Getting to goal with fixed-ratio combination therapy: Addressing unmet needs in people with Type 2 diabetes

A video-on-demand

Meeting objectives

  1. Discuss the current unmet needs and challenges for adults with Type 2 diabetes (T2D) who are not sufficiently controlled and require advancement with insulin therapy, including the treatment burden and potential adverse consequences for those on basal-bolus and premix insulin

  2. Introduce the rationale for a fixed-ratio combination (FRC) treatment to help adults with T2D reach targets and consider the patient experience when initiating this therapy versus those initiating other insulin advancement options, such as premix insulin

  3. Review clinical evidence supporting the use of a FRC of basal insulin and a glucagon-like peptide-1 receptor agonist when advancing therapy in adults with T2D

Chair's welcome

Dear Colleagues,

It is my pleasure to invite you to access a video recording of our recent live webinar, ‘Getting to goal with fixed-ratio combination therapy: Addressing unmet needs in people with Type 2 diabetes'.

Due to the progressive nature of Type 2 diabetes, many people will eventually require an insulin-based therapy in order to reach their goals. Despite several therapeutic options, glycemic targets can still be difficult to achieve, suggesting that there is an unmet need for more timely and effective forms of treatment advancement to help people reach their targets.

Therapeutic advancement with insulin therapies, such as basal-bolus or premix insulin, remains a common approach globally, but can be associated with challenges, both in terms of clinical outcomes and patient treatment burden. During this webinar, our expert panel provide insights on the unmet clinical needs and challenges associated with current insulin intensification options for adults with Type 2 diabetes. The rationale for advancement with a fixed‑ratio combination therapy to help adults with Type 2 diabetes reach their targets, as well as the patient experience of initiating this therapy, is also be discussed. Finally, we explore current and emerging clinical evidence supporting advancement of therapy using a fixed-ratio combination.

Please access this video-on-demand, which we hope will provide valuable insights that may impact your clinical practice and help to improve outcomes for your patients.

Rory McCrimmon



Rory McCrimmon (Chair)

University of Dundee, Dundee, UK

Full Biography
William Polonsky

Behavioral Diabetes Institute, San Diego, CA, USA

Full Biography
Katherine Whitmire

Southwest Medical, Las Vegas, NV, USA

Full Biography